• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

The Intersection of Pharmacists and Biotechnology: Advancements and Challenges

by MM360 Staff | May 28, 2025 | Myeloma News

Source: Pharmacy Times articles Pharmacists have an evolving role in biotechnology. Read More

FDA Approves Ustekinumab-hmny Injection, a Biosimilar Referencing Stelara

by MM360 Staff | May 28, 2025 | Myeloma News

Source: Pharmacy Times articles A new biosimilar to ustekinumab (Stelara) has been approved by the FDA, further expanding treatment options for patients with immune conditions such as plaque psoriasis and psoriatic arthritis. Read More

Navigating GLP-1 Medications: Prior Authorization Challenges and Solutions

by MM360 Staff | May 27, 2025 | Myeloma News

Source: Pharmacy Times articles The expert explored the complex prior authorization process for GLP-1 medications, discussing challenges in documentation and medical necessity. Read More

Phase 3 Trial Explores Imetelstat for Advanced Myelofibrosis After Promising Phase 2 Data

by MM360 Staff | May 27, 2025 | Myeloma News

Source: Pharmacy Times articles Imetelstat shows promise in treating myelofibrosis, enhancing survival, and modifying disease biology in patients resistant to JAK inhibitors. Read More

Five-Year Follow-Up Data Shows Zanubrutinib Improves Progression-Free Survival, Overall Survival in CLL/SLL

by MM360 Staff | May 27, 2025 | Myeloma News

Source: Pharmacy Times articles The data from the phase 3 SEQUOIA study are to be presented at the 2025 ASCO Annual Meeting. Read More

WEHI-3773 May Be Leveraged to Develop Therapeutic Strategies for Neurodegenerative Conditions

by MM360 Staff | May 27, 2025 | Myeloma News

Source: Pharmacy Times articles The small molecule effectively blocks cell death effector proteins, potentially rescuing cells from degeneration. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT